Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that the Compensation Committee of its Board of Directors granted inducement awards to two new non-executive employees under the Company's 2026 Employment Inducement Equity Incentive Plan. The awards were granted as a.